Truist analyst Robyn Karnauskas keeps a Buy rating and $1,200 price target on Regeneron (REGN), saying the 5% decline in the stock price following the denial by District Court Judge Thomas Klee of the company’s motion for a preliminary injunction against Amgen (AMGN) in its Eylea generics lawsuit is an “overreaction”. Eylea continues to be an important part of the near-term Regeneron story, but longer-term, the company has an underappreciated pipeline including oncology, immunology and inflammation, cardiovascular, etc., the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Leerink cuts Regeneron to Market Perform on Eylea franchise outlook uncertainty
- Regeneron downgraded to Market Perform from Outperform at Leerink
- Judge’s denial of Regeneron motion against Amgen a ‘speedbump’, says BMO Capital
- RBC says Regeneron reaction to biosimilar court ruling ‘overdone’
- Regeneron, Sanofi announce CHMP adopts positive opinion for Dupixent